Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/26/2025

Clinical Significance of Positive ANA by IFA with Negative Multiplex

Understanding the Discrepancy

  • IFA remains the gold standard for ANA detection and can identify a broader range of autoantibodies than multiplex assays, which test only for specific extractable nuclear antigens (ENAs), according to the European League Against Rheumatism 1
  • False negatives occur with automated multiplex methods in approximately one-third of patients because these assays may not detect antibodies to antigens whose specificity has not been determined or are not included in the panel, as reported by the American Association for the Study of Liver Diseases 2

Clinical Approach Based on IFA Pattern

  • If a homogeneous pattern is observed, order anti-dsDNA antibodies using both Crithidia luciliae immunofluorescence test (CLIFT) for specificity and solid phase assay for sensitivity, as recommended by the European League Against Rheumatism 1
  • If a speckled pattern is observed, request specific ENA testing regardless of multiplex results, as the multiplex may have missed less common specificities, according to the European League Against Rheumatism 1
  • Consider anti-ribosomal P if neuropsychiatric SLE is suspected, as suggested by the European League Against Rheumatism 1

Titer Considerations

  • Titers ≥1:160 have significantly higher clinical specificity (86.2%) and warrant aggressive follow-up regardless of multiplex results, as stated by the American College of Rheumatology 3
  • Low titers (1:40-1:80) occur in 13.3-31.7% of healthy individuals, but should still be investigated if clinical suspicion exists, according to the American College of Rheumatology 3

Critical Management Principle

  • In cases of high clinical suspicion, determination of specific antibodies should be pursued regardless of any prior negative test results, including negative multiplex, as recommended by the European League Against Rheumatism 1
  • Consider referral to a specialized reference laboratory for comprehensive autoantibody evaluation if the clinical picture strongly suggests autoimmune disease, as suggested by the American Association for the Study of Liver Diseases 2

Common Pitfalls to Avoid

  • Do not dismiss a positive IFA based solely on negative multiplex results - the IFA detects a broader antigen repertoire, as stated by the European League Against Rheumatism 1
  • Multiplex assays using ELISA can result in false negatives in about one-third of patients because they target limited antigen specificities, as reported by the American Association for the Study of Liver Diseases 2

When to Repeat Testing

  • If initial multiplex was negative but clinical suspicion remains high, request individual specific antibody testing rather than repeating the multiplex, as recommended by the European League Against Rheumatism 1
  • For diagnosed SLE, use quantitative anti-dsDNA by the same method consistently for monitoring, not repeat ANA testing, as suggested by the European League Against Rheumatism and the American College of Rheumatology 1, 3